医学临床研究
  2025年6月15日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (1): 53-56    DOI: 10.3969/j.issn.1671-7171.2023.01.016
  论著 本期目录 | 过刊浏览 | 高级检索 |
沙利度胺联合精确放疗同步化疗对食管癌患者血清miR-451、miR-21水平及预后的影响
王立燕, 刘晓霞
山东省立第三医院肿瘤中心,山东 济南 250031
Effects of Thalidomide Combined with Precise Radiotherapy and Chemotherapy on Serum miR-451 and miR-21 Levels and Prognosis in Patients with Esophageal Cancer
WANG Li-yan, LIU Xiao-xia
Department of Tumor center,Shandong Provincial Third Hospital,Jinan Shandong 250031
全文: PDF (1129 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 探讨沙利度胺联合精确放疗同步化疗对食管癌患者血清微小RNA-451(miR-451)、微小RNA-21(miR-21)水平及预后的影响。【方法】 96例食管癌患者,随机分为两组,每组48例。对照组给予精确放疗同步化疗,观察组给予沙利度胺联合精确放疗同步化疗。治疗2个月后,比较两组近期疗效、不良反应发生率、随访结果及治疗前后血清癌胚抗原(CEA)、糖类抗原125(CA125)、巨噬细胞炎性蛋白-3α(MIP-3α)、miR-451、miR-21水平。【结果】 观察组疾病缓解率为70.83%,明显高于对照组的50.00%(P<0.05)。观察组放射性食管炎和血液毒性发生率明显低于对照组(P<0.05);两组放射性气管炎、食管狭窄、肺纤维化发生率比较,差异无统计学意义(P>0.05)。治疗后,两组血清CEA、CA125、MIP-3α水平和miR-451、miR-21水平较治疗前明显降低(P<0.05),且观察组明显低于对照组(P<0.05)。观察组3年累积生存率为58.70%,明显高于对照组的33.33%(P<0.05)。【结论】 与精确放疗同步化疗相比,沙利度胺联合精确放疗同步化疗治疗食管癌近远期疗效更为确切,可下调肿瘤标志物水平和血清miR-451、miR-21水平,降低放射性食管炎和血液毒性的发生风险。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
王立燕
刘晓霞
关键词 食管肿瘤/放射疗法 食管肿瘤/药物疗法 沙利度胺 微RNAs    
Abstract【Objective】 To investigate the effect of thalidomide combined with precise radiotherapy and concurrent chemotherapy on serum microrRNA-451 (miR-451) and microrRNA-21 (miR-21) levels and prognosis in patients with esophageal cancer.【Methods】 A total of 96 patients with esophageal cancer were randomly divided into two groups,with 48 cases in each group.The control group was given precise radiotherapy combined with concurrent chemotherapy,while the observation group was given thalidomide combined with precise radiotherapy and chemotherapy.After 2 months of treatment,the short-term efficacy,incidence of adverse reactions,serum levels of carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA125),macrophage inflammatory protein-3α(MIP-3α),miR-451,miR-21 and follow-up results were compared between the two groups before and after treatment.【Results】 The disease remission rate of the observation group was 70.83%,which was significantly higher than that of the control group (50.00%,P<0.05).The incidence of radiation esophagitis and hematotoxicity in the observation group was significantly lower than that in the control group (P<0.05).There was no significant difference in the incidence of radiation bronchitis,esophageal stenosis and pulmonary fibrosis between the two groups (P>0.05).After treatment,the serum levels of CEA,CA125,MIP-3α,miR-451 and miR-21 in the two groups were significantly lower than those before treatment (P<0.05),and the observation group was significantly lower than the control group (P<0.05).The 3-year cumulative survival rate of the observation group was 58.70%,which was significantly higher than that of the control group (33.33%) (P<0.05).【Conclusion】 Compared with precise radiotherapy and concurrent chemotherapy,thalidomide combined with precise radiotherapy and concurrent chemotherapy has more accurate short-term and long-term efficacy in the treatment of esophageal cancer.It can lower the level of tumor markers and serum miR-451,miR-21 levels,and reduce the risk of radiation esophagitis and blood toxicity.
Key wordsEsophageal Neoplasms/RT    Esophageal Neoplasms/DT    Thalidomide    MicroRNAs
收稿日期: 2022-03-01     
中图分类号:  R735.1  
引用本文:   
王立燕, 刘晓霞. 沙利度胺联合精确放疗同步化疗对食管癌患者血清miR-451、miR-21水平及预后的影响[J]. 医学临床研究, 2023, 40(1): 53-56.
WANG Li-yan, LIU Xiao-xia. Effects of Thalidomide Combined with Precise Radiotherapy and Chemotherapy on Serum miR-451 and miR-21 Levels and Prognosis in Patients with Esophageal Cancer. JOURNAL OF CLINICAL RESEARCH, 2023, 40(1): 53-56.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.01.016     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I1/53
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn